<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Brand, Stephen R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">VT-1161 Emerges as Potential Treatment for Acute Vulvovaginal Candidiasis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-23 15:14:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-19</style></pages><abstract><style  face="normal" font="default" size="100%">The novel agent VT-1161 is safe and as effective as fluconazole for treating acute vulvovaginal candidiasis infections. Furthermore, it is more effective than fluconazole for preventing recurrent vulvovaginal candidiasis infections, particularly at its mid- and high doses, according to results from a phase 2 dose-ranging study. VT-1161 is now being evaluated in patients with recurrent vulvovaginal candidiasis in the REVIVE trial.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>